Allakos Stock News

ALLK stock dropped off a cliff following disappointing study results, which illustrates what can go wrong in risky biopharma equities. The post Allakos Is a Cautionary Tale of Biopharmaceutical Invest

The biotech stock is now down roughly 93% over the last year.

The biotech stock is now down roughly 93% over the last year.

The biotech stock is now down roughly 93% over the last year.

After a well-publicized clinical-data letdown, it may be time to go long as the worst-case scenario has already been priced into ALLK stock. The post After a Clinical-Data Bombshell, Allakos Might Act

Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima

Here is how AbbVie (ABBV) and Allakos Inc. (ALLK) have performed compared to their sector so far this year.

Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima

Allakos Inc (ALLK) shares closed today 22.2% higher than it did at the end of yesterday. The stock is currently down 92.5% year-to-date, down 93.1% over the past 12 months, and down 66.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $84.94 and as low as $8.44 this week.Shares closed 93.4% below its 52-week high and 23.8% above its 52-week low.Trading volume this week was 52.7% higher than the 10-day average and 593.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 862.6% The company's stock price performance over the past 12 months lags the peer average by 689.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment. The week's news w

Allakos Inc (ALLK) shares closed today 22.2% higher than it did at the end of yesterday. The stock is currently down 92.5% year-to-date, down 93.1% over the past 12 months, and down 66.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $84.94 and as low as $8.44 this week.Shares closed 93.4% below its 52-week high and 23.8% above its 52-week low.Trading volume this week was 89.7% higher than the 10-day average and 593.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 862.6% The company's stock price performance over the past 12 months lags the peer average by 689.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available on Seeking Alpha, iTunes, Stitcher and Spotify. U.S.

Allakos (NASDAQ:ALLK) had its target price decreased by The Goldman Sachs Group from $122.00 to $60.00 in a research report report published on Thursday morning, Analyst Ratings Network reports. The Goldman Sachs Group currently has a neutral rating on the stock. A number of other analysts have also commented on ALLK. Jefferies Financial Group lowered []

This Nasal Polyposis Drug market research stud offers proper industry viewpoint, market size, growth, future trends and trading. All this are taken into consideration while preparing the market report with the forecast period from 2021 to 2027. This report

Allakos (NASDAQ:ALLK) was downgraded by analysts at Cowen from an outperform rating to a market perform rating in a report released on Wednesday, Price Targets.com reports. Several other analysts have also recently issued reports on ALLK. Zacks Investment Research upgraded shares of Allakos from a sell rating to a hold rating in a research note []